WARFARIN NECROSIS TREATMENT with TRANSDERMAL CONTINUOUS OXYGEN THERAPY Stephanie Wu, DPM, MSc* and Donald Kemp, MD# * Associate Professor of Surgery, Dr. William M. Scholl College of Podiatric Medicine, Center for Lower Extremity Ambulatory Research, Chicago IL #Renfrew Victoria Hospital, Wound care Clinic, Renfrew, ON, Canada
Warfarin (Coumadin; DuPont Pharma, Wilmington, DE) is a synthetic derivative of coumarin, a chemical found naturally in many plants. It has been used for years as an effective and
relatively safe pharmacologic agent for the prevention of thrombosis and embolism, and is the most widely prescribed anticoagulant in North America1. Despite its popularity and
effectiveness, the use of Warfarin has several associated morbidities including hemorrhagic complications, interactions with other medications, the need for frequent monitoring of
international normalized ratio (INR), teratogenicity, and Warfarin induced skin necrosis (WISN)2-5.
WISN is relatively rare considering the widespread use of the agent and is also known as Coumadin induced skin necrosis, coumarin-congener-associated skin necrosis, and Warfarin
dermal gangrene6, 7. The exact incidence of WISN is undetermined but estimated to be between 0.01 - 0.1% of patients treated with Warfarin, with approximately 200 documented
The presentation of WISN may mimic other disorders including venous gangrene, necrotizing fasciitis, other causes of skin necrosis, and dermatological entities13, 14. WISN seems to
have a marked predilection for anatomic regions abundant in subcutaneous fat such as the breasts, buttocks, thighs, and abdomen4, 9,15-17. WISN classically presents with a painful skin
lesion or petechaiae that progress to a localized, initially erythematous or hemorrhagic sharply demarcated ecchymosis that become bullous and eventually culminates into tender,
crusted, full thickness gangrenous necrosis5, 9, 10, 12, 18.
We present patient with WISN of bilateral shoulder area that was successfully treated with a Transdermal Continuous Oxygen Therapy device (TCOT) (EPIFLO®, Ogenix Corporation,
Beachwood, OH). We will discuss the management challenges involved as aggressive surgical debridement is not possible with this disorder and as a result, a more conservative
management strategy was used, which may be considered for future therapies. A 62 year old female presented to the wound care clinic for treatment of extensive wounds on both shoulders and abdomen in August of 2007. The wounds began about a year
before but were stable until about 2 weeks prior to initial treatment with Transdermal Continuous Oxygen Therapy. The patient had been on Warfarin therapy for 27 years, long term
dialysis, was diagnosed with breast cancer 3 years prior, and has since had a double mastectomy. Patient was noted to have both protein C and protein S defi ciency, and palliative
treatment was recommended by the treating physician. Initially, TCOT was applied to the right shoulder wound while negative pressure wound therapy (NPWT) (Wound VAC, KCI,
San Antonio, TX) was applied to the left. The patient willingly underwent the comparative treatment and was advised that the extensive eschar and slough may act as a diffusional
barrier for the oxygen therapy. It should be noted that as the patient was being treated with an anticoagulant, debridement was not performed to remove any necrotic tissue, making
treatment more diffi cult. After 1 week of treatment, the patient was deemed non-compliant as she was unable to tolerate the pain associated with NPWT on the left shoulder, and
may have intentionally removed the TCOT device on the right shoulder and was subsequently placed on standard moist wound therapy. Over a month later, the wounds remained
recalcitrant to standard moist wound therapy treatment. TCOT was then reinitiated on the right side fl ank wound. The patient then complained of immense pain in the left shoulder
Left Shoulder Wound after 2 weeks w/ TCOT
Left Shoulder Wound after 22 weeks w/ TCOT
and was eventually diagnosed with calciphylaxis. After 1 week, the right side fl ank wound was observed with some noted improvement including reduction of size, shape change of
wound, defi ned wound edges, reduction of slough and increased granulation and a size of 11cm x 4.5 cm. The patient continued to complain of immense pain while numerous new
wounds concomitantly formed. Subsequent to the success with the right fl ank wound after 1 week, the treating physician initiated TCOT on the left shoulder wound. The right shoulder
wound which remained treated only with moist wound therapy, showed a lack of granulation and appeared less healthy than those treated with TCOT. The patient was prescribed
This case is interesting in that TCOT device demonstrated effi cacy in healing recalcitrant wounds secondary to Warfarin necrosis when compared to standard of care treatments.
Dilaudid for the pain and received silicone based foam dressing (Mepilex, Mölnlycke Health Care US, Norcross, GA) on all other wounds since regular gauze dressings (applied by
Transdermal continuous oxygen therapy may serve as an effi cacious alternative treatment option for patients especially when other advanced treatment modalities such as NPWT may
home care nurse between visits to the clinic) became adhered to wound tissues. The right side fl ank wound and left shoulder wounds showed consistent and continuous improvement
be too painful and not well tolerated in this patient population.
including a continued reduction in slough and eschar and increased granulation, nonetheless, the wound on the right shoulder was not treated with TCOT. After 3 weeks and 2 weeks
respectively, the right fl ank had now reduced in size to 9.0 cm x 3.5 cm with signifi cant improvement in granulation and wound margin health and the left shoulder wound changed
shape and reduced to 2 smaller wounds joined by an isthmus and measured 5.2 cm x 4.2 cm and 3.5 cm x 2.5 cm. The untreated right shoulder wound (treated only with standard
moist wound therapy treatment) measured 4.5 cm x 3 cm, lacked granulation tissue and appeared less healthy than TCOT treated wounds. Interestingly, the patient reported a change
As surgical treatment is required in over 50 % of all cases, including mastectomies and amputations19, TCOT may serve as an effi cacious non
in pain from burning and extremely painful to more tolerable puritic type of sensation after two weeks of TCOT treatment; complete resolution of pain resulted in all wounds treated
invasive alternative to help treat WISN and its associated painful symptoms.
with the TCOT device after a month. After 4 weeks and 3 weeks respectively, the right fl ank wound decreased in size to 7 cm x 1.5 cm, and the left shoulder decreased to 3 x 1.5 cm
and 4.2 cm x 2.5 cm. The untreated right shoulder wound (treated only with standard moist wound therapy treatment) increased in size to5.4cm x 1.4 cm.
1. Jillella AP, Lutcher CL. Reinstituting Warfarin in patients who develop Warfarin skin necrosis. Am JHematol. Jun 1996;52(2):117-119.
11. Sallah S, Abdallah JM, Gagnon GA. Recurrent warfarin-induced skin necrosis in kindreds with protein S defi ciency. Haemostasis. Jan-Feb 1998;28(1):25-30.
The left shoulder wound and right fl ank wound continued to heal with complete epithelialization noted in 22 weeks or about 5.4 months and wounds in close
2. Shetty HG, Woods F, Routledge PA. The pharmacology of oral anticoagulants: implications for therapy. JHeart Valve Dis. Jan 1993;2(1):53-62.
12. Ad-E1 DD, Meirovitz A, Weinberg A, et al. Warfarin skin necrosis: local and systemic factors. Br J Plast Surg. Oct 2000;53(7):624-626.
3. Berkompas DC. Coumadin skin necrosis in a patient with a free protein S defi ciency: case report and literature review. Indiana Med. Nov 1991;84(11):788 791.
13. Chan YC, Valenti D, Mansfi eld AO, Stansby G. Warfarin induced skin necrosis. Br J Surg. Mar 2000;87(3):266-272.
proximity to treated wounds improved as well. As time progressed, the wounds treated with TCOT continued to demonstrate excellent granulation and the wounds
4. Warkentin TE, Sikov WM, Lil icrap DP. Multicentric warfarin-induced skin necrosis complicating heparin-induced thrombocytopenia. Am J Hematol. Sep 1999;62(l):44-48.
14. Gelwix TJ, Beeson MS. Warfarin-induced skin necrosis. Am J Emerg Med. Sep 1998;16(5):541-543.
that were in close proximity to the topical oxygen treated wounds but not treated with the device were slowly showing improvement including the untreated right shoulder
5. Egred M, Rodrigues E. Purple digit syndrome and warfarin-induced skin necrosis. EurJIntern Med. Aug 2005;16(4):294-295.
15. Bahadir I, James EC, Fedde CW. Soft tissue necrosis and gangrene complicating treatment with the coumarin derivatives. Surg Gynecol Obster Oct 1977;145(4):497-500.
6. McKnight JT, Maxwell AJ, Anderson RL. Warfarin necrosis. Arch Earn Med. Sep 1992;1(1):105-108.
16. Stone MS, Rosen T. Acral purpura: an unusual sign of coumarin necrosis. J Am Acad DermatoL May 1986;14(5 Pt 1):797-802.
wound (treated only with standard moist wound therapy treatment). The patient’s outlook and demeanor also noticeably improved. Three months after presenting to
7. Gailani D, Reese EP, Jr. Anticoagulant-induced skin necrosis in a patient with hereditary defi ciency of protein S. Am J HematoL Mar 1999;60(3):231-236.
17. Martinez Del Pero M, Verma S, Espeso A, Griffi ths M, Jani P. An unusual case of warfarin-induced pinna skin necrosis. J Latyngol OtoL Jun 2009;123(6):685-688.
the wound clinic, Warfarin was discontinued by the treating physician and heparin therapy initiated. After almost 8 months following the initial presentation to the
8. Viegas GV. Coumadin skin necrosis. Pedal manifestations. J Am Podiatr Med Assoc. Sep 1992;82(9):463-470.
18. Brooks LW, Jr., Blais FX. Coumarin-induced skin necrosis. J Am Osteopath Assoc. Jun 1991;91(6):601-605.
9. Miura Y, Ardenghy M, Ramasastry S, Kovach R, Hochberg J. Coumadin necrosis of the skin: report of four patients. Ann Plast Surg. Sep 1996;37(3):332-337.
19. Beitz, J.M. Coumadin-induced Skin Necrosis. Wounds Aug 15 2002; 14(6):217-2
clinic, the patient was completely healed and very happy with the results.
10. Sternberg ML, Pettyjohn FS. Warfarin sodium-induced skin necrosis. Ann Emerg Med. Jul 1995;26(1):94-97.
CONVENTION INTERNATIONALE CONTRE LE DOPAGE DANS LE SPORT Annexe I - Liste des interdictions - Standard international LISTE DES INTERDICTIONS 2011 CODE MONDIAL ANTIDOPAGE Entrée en vigueur le 1er janvier 2011 Toutes les substances interdites doivent être considérées comme des « substances spécifiées » sauf les substances dans les classes S1, S2.1 à S2.5, S4.4 e
APPLICATION FOR MEMBERSHIP MEDIMED MEDICAL SCHEME P.O. Box 1672 7 Lutman Road CALL CENTRE 041-395 4474 Port Elizabeth Richmond Hill E-MAIL ADDRESS [email protected] Port Elizabeth www.providence.co.za SECTION 1 PERSONAL DETAILS Please select one option by placing an "X" in the appropriate box SECTION 2 YOUR OPTION Please select one option by p